%0 Journal Article
%T Individualization of the Dosage Regimen of Erythropoietin is Crucial in End-stage Renal Disease Patients.
%A Krishnapriya MK
%A Karthika S
%A Babu A
%A Tom AA
%J Saudi J Kidney Dis Transpl
%V 34
%N 5
%D 2023 Sep 1
%M 38995309
暂无%R 10.4103/1319-2442.397212
%X The objective of this study was to understand the utilization pattern of erythropoietin in end-stage renal disease patients, along with the effect of body weight and sex on the patients' responses. In this retrospective single-center study, 120 patients were included who were on a once weekly (n = 79), twice weekly (n = 37), or thrice weekly (n = 4) regimen. The doses of erythropoiesis-stimulating agents (ESA) were collected, and the erythropoietin resistance index (ERI) was determined. The Kruskal-Wallis test was used to evaluate the dose schedules, and the once-weekly regimen produced a greater response (P = 0.001). The asymptotic significance of Pearson's Chi-square-test equating the mean ERI and body mass index (BMI) was 0.034. No statistically significant correlation was estimated between sex and mean ERI (P = 0.201). Our study demonstrated that the once-weekly regimen dominated over the others in terms of efficacy, and individuals with a higher BMI were found to respond better to the ESA therapy.